105 related articles for article (PubMed ID: 18972879)
1. [Instructions and methods for clinical trials of medicinal products for the treatment of chronic systolic heart failure].
Wink K
Arzneimittelforschung; 2008; 58(9):475-9. PubMed ID: 18972879
[TBL] [Abstract][Full Text] [Related]
2. [Design and method of clinical trials of drugs used in the therapy of stable peripheral arterial occlusive disease].
Wink K
Arzneimittelforschung; 2006; 56(1):52-7. PubMed ID: 16478006
[TBL] [Abstract][Full Text] [Related]
3. [Guidelines and methods for clinical investigation of drugs for treatment of stable angina pectoris].
Wink K
Arzneimittelforschung; 2003; 53(12):864-8. PubMed ID: 14732968
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
5. Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
Pan L; Payne J; Clark M
J Okla State Med Assoc; 2011 Feb; 104(2):49-50. PubMed ID: 21815321
[No Abstract] [Full Text] [Related]
6. Instructions and methods for clinical testing of drugs for the treatment of atrial fibrillation.
Wink K
Arzneimittelforschung; 2010; 60(12):776-9. PubMed ID: 21265470
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?
Abate E; Sartor R; Ceconi C; Boffa GM
J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):893-905. PubMed ID: 20414119
[TBL] [Abstract][Full Text] [Related]
8. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.
Flannery G; Gehrig-Mills R; Billah B; Krum H
Am J Cardiol; 2008 Mar; 101(6):865-9. PubMed ID: 18328855
[TBL] [Abstract][Full Text] [Related]
9. General statistical design considerations of randomized clinical trials.
Peduzzi P
Prog Clin Biol Res; 1988; 264():61-70. PubMed ID: 3289035
[TBL] [Abstract][Full Text] [Related]
10. [Patients with cardiovascular risk. SH/fT study: mortality rate reduced by a fourth].
MMW Fortschr Med; 2010 Oct; 152(40):54-5. PubMed ID: 21049647
[No Abstract] [Full Text] [Related]
11. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.
Kohro T; Yamazaki T
Hypertens Res; 2009 Feb; 32(2):109-14. PubMed ID: 19262468
[TBL] [Abstract][Full Text] [Related]
12. SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
Cardiovasc J Afr; 2012 Jul; 23(6):360. PubMed ID: 23961539
[No Abstract] [Full Text] [Related]
13. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?
Correale M; Ieva R; Di Biase M
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):373. PubMed ID: 21451336
[No Abstract] [Full Text] [Related]
15. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the COPPS trial: a randomised, placebo-controlled, multicentre study on the use of colchicine for the primary prevention of postpericardiotomy syndrome.
Imazio M; Cecchi E; Demichelis B; Chinaglia A; Coda L; Ghisio A; Demarie D; Ierna S; Trinchero R;
J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1044-8. PubMed ID: 18163018
[TBL] [Abstract][Full Text] [Related]
17. A review of heart failure management in the elderly population.
Cheng JW; Nayar M
Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
[TBL] [Abstract][Full Text] [Related]
18. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
[No Abstract] [Full Text] [Related]
19. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
20. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
